FreeOx Biotech has taken on AEC Partners as a strategic partner in the company to accelerate development and marketing of its drug to treat brain ischemia.
The priority drug is Ox-01, which is about to begin phase-III clinical trials. AEC Partners analysed the brand positioning, financial needs and expected return. At the same time, negotiations are already under way with potential licensees in various world markets.
AEC Partners is a consultancy specialising in the healthcare and life sciences sector. With an office in Barcelona since 2016, the firm has more than 20 years of experience managing international projects from its headquarters in Paris. In line with the growing importance of start-ups as a source of innovation, the companyis deeply involved in providing strategic guidance, valorisation (for industry and funds), support in thesearch for funding, business development and international expansion.
Jordi Esclusa, managing partner at AEC Partners, and Nerea Alonso, partner in the Barcelona offices of AEC Partners, explain that “It is highly satisfying to lead a project of this size from Barcelona and to help bring a drug to market in a therapeutic area with so many unmet needs, with great clinical and social impact.”
Carlos Lurigados, co-founder and CEO of FreeOx, believes that taking AEC Partners on as shareholders “will allow us to consolidate the development of Ox-01 being carried out by Dr Àngel Chamorro at Hospital Clinic Barcelona, orientate it to the market and, in short, boost its value for potential licensees.”
Both companies are members of CataloniaBio & HealthTech.
In the photo, from left to right, Jordi Esclusa, Nerea Alonso, Carlos Lurigados, Dr Ángel Chamorro and Philippe Coriat.
